Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology

被引：28

作者：

de Waal, L

Wyatt, LS

Yüksel, S

van Amerongen, G

Moss, B

Niesters, HGM

Osterhaus, ADME

de Swart, RL

机构：

[1] Erasmus MC, Dept Virol, NL-3000 DR Rotterdam, Netherlands

[2] NIAID, Viral Dis Lab, NIH, Bethesda, MD USA

来源：

VACCINE | 2004年 / 22卷 / 08期

关键词：

MVA; RSV; immunopathology;

D O I：

10.1016/j.vaccine.2003.10.010

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We have evaluated the safety and immunogenicity of a recombinant modified vaccinia virus Ankara (MVA) vector expressing the respiratory syncytial virus (RSV) fusion (F) and attachment (G) proteins in infant macaques. Animals were vaccinated twice and 4 months later challenged with RSV. Although vaccination did not predispose for immunopathology upon challenge, we were also unable to demonstrate protection. Since vaccination had resulted in priming for secondary immune responses upon challenge, we suggest that vaccination efficacy will have to be improved by using MVA in a prime-boost strategy. (C) 2003 Elsevier Ltd. All rights reserved.

引用

收藏

页码：923 / 926

页数：4

相关论文

共 19 条

[1] Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus [J].

Chen, M ;

Hu, KF ;

Rozell, B ;

Örvell, C ;

Morein, B ;

Lijeström, P .

JOURNAL OF IMMUNOLOGY, 2002, 169 (06) :3208-3216

[2] Respiratory syncytial virus: Reverse genetics and vaccine strategies [J].

Collins, PL ;

Murphy, BR .

VIROLOGY, 2002, 296 (02) :204-211

[3] Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara [J].

Hirsch, VM ;

Fuerst, TR ;

Sutter, G ;

Carroll, MW ;

Yang, LC ;

Goldstein, S ;

Piatak, M ;

Elkins, WR ;

Alvord, WG ;

Montefiori, DC ;

Moss, B ;

Lifson, JD .

JOURNAL OF VIROLOGY, 1996, 70 (06) :3741-3752

[4]

HSU KHL, 1992, J INFECT DIS, V166, P769, DOI 10.1093/infdis/166.4.769

[5] Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge [J].

Kahn, JS ;

Roberts, A ;

Weibel, C ;

Buonocore, L ;

Rose, JK .

JOURNAL OF VIROLOGY, 2001, 75 (22) :11079-11087

[6] Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques [J].

Nilsson, C ;

Sutter, G ;

Walther-Jallow, L ;

ten Haaft, P ;

Åkerblom, L ;

Heeney, J ;

Erfle, V ;

Böttiger, P ;

Biberfeld, G ;

Thorstensson, R .

JOURNAL OF GENERAL VIROLOGY, 2002, 83 :807-818

[7] EVALUATION IN NON-HUMAN PRIMATES OF THE SAFETY, IMMUNOGENICITY AND EFFICACY OF RECOMBINANT VACCINIA VIRUSES EXPRESSING THE F-GLYCOPROTEIN OR G-GLYCOPROTEIN OF RESPIRATORY SYNCYTIAL VIRUS [J].

OLMSTED, RA ;

BULLER, RML ;

COLLINS, PL ;

LONDON, WT ;

BEELER, JA ;

PRINCE, GA ;

CHANOCK, RM ;

MURPHY, BR .

VACCINE, 1988, 6 (06) :519-524

[8] Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults [J].

Power, UF ;

Nguyen, TN ;

Rietveld, E ;

de Swart, RL ;

Groen, J ;

Osterhaus, ADME ;

de Groot, R ;

Corvaia, N ;

Beck, A ;

Bouveret-le-Cam, N ;

Bonnefoy, JY .

JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (11) :1456-1460

[9]

REED L. J., 1938, AMER JOUR HYG, V27, P493

[10] Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3 [J].

Schmidt, AC ;

McAuliffe, JM ;

Murphy, BR ;

Collins, PL .

JOURNAL OF VIROLOGY, 2001, 75 (10) :4594-4603